Advanced

A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.

Berntorp, Erik LU ; Keeling, D; Makris, M; Tagliaferri, A; Carlström, M; Mauser-Bunschoten, E P; Musso, R; Roca, C A; Hassoun, A and Kollmer, C, et al. (2012) In Haemophilia 18(4). p.503-509
Abstract
Summary. Nonacog alfa, a recombinant factor IX (FIX) used for the treatment of haemophilia B, was approved in Europe in 1998. In accordance with European Medicines Agency requirements, a registry study was conducted from 2002 to 2009. A reformulated iso-osmotic version was approved for European use in 2007. This study was conducted to evaluate the safety of nonacog alfa in a usual care setting, and provide clinical trial and postmarketing surveillance data support. This open-label, non-interventional, prospective observational cohort study (registry) comprised 52 sites in nine European countries. Patients with haemophilia B receiving nonacog alfa in either formulation for prevention or treatment were followed on a usual care schedule. A... (More)
Summary. Nonacog alfa, a recombinant factor IX (FIX) used for the treatment of haemophilia B, was approved in Europe in 1998. In accordance with European Medicines Agency requirements, a registry study was conducted from 2002 to 2009. A reformulated iso-osmotic version was approved for European use in 2007. This study was conducted to evaluate the safety of nonacog alfa in a usual care setting, and provide clinical trial and postmarketing surveillance data support. This open-label, non-interventional, prospective observational cohort study (registry) comprised 52 sites in nine European countries. Patients with haemophilia B receiving nonacog alfa in either formulation for prevention or treatment were followed on a usual care schedule. A total of 218 patients were enrolled, of whom 66 (30.3%) were <18 years of age. Haemophilia severity was evenly distributed, with baseline FIX activity of <1%, 1-5% and >5% in 33.3%, 36.6% and 30.1% of patients, respectively. One hundred thirty-eight patients received the original formulation alone; 80 switched to or received only the new formulation. There was a low incidence of events of special interest (ESIs), with less-than-expected therapeutic effect in five patients (2.2%), inhibitor development in two (0.9%), thrombosis in one (0.5%) and allergic events in eight (3.7%). These accounted for the majority of the 15 serious AEs reported in six patients. Six patients discontinued because of AEs, primarily related to hypersensitivity. Nonacog alfa was shown to be safe for the treatment of haemophilia B, with a low incidence of serious AEs and ESIs. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Haemophilia
volume
18
issue
4
pages
503 - 509
publisher
Federation of European Neuroscience Societies and Blackwell Publishing Ltd
external identifiers
  • wos:000305824400014
  • pmid:22044794
  • scopus:84863315296
ISSN
1351-8216
DOI
10.1111/j.1365-2516.2011.02685.x
language
English
LU publication?
yes
id
81c087ef-c027-43dd-970a-80976a85d055 (old id 2221306)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/22044794?dopt=Abstract
date added to LUP
2011-12-02 18:26:17
date last changed
2017-11-19 03:08:02
@article{81c087ef-c027-43dd-970a-80976a85d055,
  abstract     = {Summary. Nonacog alfa, a recombinant factor IX (FIX) used for the treatment of haemophilia B, was approved in Europe in 1998. In accordance with European Medicines Agency requirements, a registry study was conducted from 2002 to 2009. A reformulated iso-osmotic version was approved for European use in 2007. This study was conducted to evaluate the safety of nonacog alfa in a usual care setting, and provide clinical trial and postmarketing surveillance data support. This open-label, non-interventional, prospective observational cohort study (registry) comprised 52 sites in nine European countries. Patients with haemophilia B receiving nonacog alfa in either formulation for prevention or treatment were followed on a usual care schedule. A total of 218 patients were enrolled, of whom 66 (30.3%) were &lt;18 years of age. Haemophilia severity was evenly distributed, with baseline FIX activity of &lt;1%, 1-5% and &gt;5% in 33.3%, 36.6% and 30.1% of patients, respectively. One hundred thirty-eight patients received the original formulation alone; 80 switched to or received only the new formulation. There was a low incidence of events of special interest (ESIs), with less-than-expected therapeutic effect in five patients (2.2%), inhibitor development in two (0.9%), thrombosis in one (0.5%) and allergic events in eight (3.7%). These accounted for the majority of the 15 serious AEs reported in six patients. Six patients discontinued because of AEs, primarily related to hypersensitivity. Nonacog alfa was shown to be safe for the treatment of haemophilia B, with a low incidence of serious AEs and ESIs.},
  author       = {Berntorp, Erik and Keeling, D and Makris, M and Tagliaferri, A and Carlström, M and Mauser-Bunschoten, E P and Musso, R and Roca, C A and Hassoun, A and Kollmer, C and Charnigo, R and Baumann, J and Rendo, P},
  issn         = {1351-8216},
  language     = {eng},
  number       = {4},
  pages        = {503--509},
  publisher    = {Federation of European Neuroscience Societies and Blackwell Publishing Ltd},
  series       = {Haemophilia},
  title        = {A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.},
  url          = {http://dx.doi.org/10.1111/j.1365-2516.2011.02685.x},
  volume       = {18},
  year         = {2012},
}